Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,563 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

UCLA Magnesium Formulation Athlete Study

NCT07640685
View directory record Official record
Conditions
Athletic Performance, Recovery, Sleep
Interventions
Magnesium glycinate, Magnesium L-threonate, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

NCT03694522
View directory record Official record
Conditions
Gastric Cancer
Interventions
Bemarituzumab, Placebo, Modified FOLFOX6
Biological · Drug
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Telehealth Intervention for Improved Blood Pressure Control With Targeted Incentives

NCT04075045
View directory record Official record
Conditions
Hypertension, Non-Adherence, Patient
Interventions
Wellth Smartphone App, Targeted Incentives, Non-Restricted Incentives
Behavioral
Lead sponsor
Wellth Inc.
Industry
Eligibility
50 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Traveler's Diarrhea (TD) Automated Process

NCT00751777
View directory record Official record
Conditions
Prevention of Travelers' Diarrhea
Interventions
heat-labile enterotoxin of E. coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Vallejo, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)

NCT00708981
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Multifactorial Intervention
Other
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Placebo, Enicepatide
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Orca-T, Standard-of-Care
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Phase 3 Interventional

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

NCT07006675
View directory record Official record
Conditions
Tibial Fractures, Pain
Interventions
600 mg Ibuprofen
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Cambridge, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Exercise and Spinal Cord Injury

NCT03941600
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Community-based Exercise Intervention group (CBE), Exercise Education Control group (EEG)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01813019
View directory record Official record
Conditions
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
San Diego, California • Watertown, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 23, 2026, 4:22 AM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

NCT00317395
View directory record Official record
Conditions
Coronary Disease
Interventions
Otamixaban (XRP0673), unfractionated heparin, eptifibatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 23, 2026, 4:22 AM EDT
Not listed Not applicable Interventional

Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients

NCT05884944
View directory record Official record
Conditions
Parkinson Disease, Osteopathy in Diseases Classified Elsewhere
Interventions
Sham- Light touch, not reaching restrictive barrier, Experimental: Interventional Group- OMM- Muscle energy
Procedure
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

NCT02861157
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Planet T1D
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

NCT05047601
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Placebo for PF-07321332, Placebo for Ritonavir, Ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
64
States / cities
Pelham, Alabama • Tucson, Arizona • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Technology Intensified Diabetes Education Study in African Americans

NCT02088658
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Technology Intensified
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Not listed Phase 2 Interventional

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

NCT01265576
View directory record Official record
Conditions
HCC
Interventions
Sorafenib, VT-122 (propranolol plus etodolac), Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

NCT01020006
View directory record Official record
Conditions
Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions
PCI-27483, Gemcitabine
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated Phase 1Phase 2 Interventional

Fecal Microbial Transplant in Pediatric Crohn's Disease

NCT02272868
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fecal Microbial transplant, Normal Saline, rifaximin+omeprazole+miralax
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 23, 2026, 4:22 AM EDT
Recruiting Not applicable Interventional

Vestibular Therapy in Alzheimer's Disease

NCT03799991
View directory record Official record
Conditions
Vestibular Diseases, Vestibular Disorder, Alzheimer Disease
Interventions
Vestibular physical therapy, Active control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 4:22 AM EDT
Terminated No phase listed Observational

The Effect of Ketogenic Dietary Therapy on Sleep in Adult Epilepsy

NCT04193891
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Modified Atkins Diet
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 23, 2026, 4:22 AM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 23, 2026, 4:22 AM EDT